The first large, real-world study of the effectiveness of mRNA COVID-19 vaccines during pregnancy found these vaccines, especially two initial doses followed by a booster, are effective in protecting against serious disease in expectant mothers whether the shots are administered before or during pregnancy.
Pregnant women were excluded from COVID-19 mRNA vaccine clinical trials, so this new study fills a significant knowledge gap, providing strong evidence that vaccinating women who are or might become pregnant protects against hospitalization for the disease during pregnancy.
“That two doses plus a booster are known to be safe and demonstrate protection against severe disease in pregnant women is reassuring, given growing evidence of increased risk of poor maternal outcomes associated with COVID-19 infection during pregnancy,” said study co-author Brian Dixon, PhD, MPA, director of public health informatics for Regenstrief Institute and Indiana University Richard M. Fairbanks School of Public Health. “This strongly suggests that, along with other preventive measures that expectant mothers or women who are considering getting pregnant can take to promote a healthy pregnancy, getting vaccinated and boosted against COVID should be high on the list.” Dr. Dixon also is the interim director of the Regenstrief Center for Biomedical Informatics.
The researchers found that mRNA COVID-19 vaccination protects pregnant women against emergency department (E.D.) or urgent care center visits and protects even more strongly against hospitalizations for COVID-19, three venues for receipt of medical attention for the disease. As with other evaluations of mRNA COVID-19 vaccines in adults, a lower effectiveness in protecting against E.D. and urgent care visits than for hospitalizations was seen in pregnant women, most significantly in the Omicron period among those receiving only two vaccine doses.
Also, similar to findings among non-pregnant adults, two-dose protection waned over time (after four months) and vaccine effectiveness was highest among pregnant women with three doses (initial two vaccinations plus a booster shot).
Data on a total of 3,445 E.D. or urgent care visits and 781 hospitalizations among pregnant women with COVID-19 confirmed by molecular testing was extracted from electronic medical records from 306 hospitals and 164 E.D. and urgent care facilities in eight health systems across 10 U.S. states. This information was analyzed by the VISION network, which includes Baylor Scott & White Health (Texas), Columbia University Irving Medical Center (New York), HealthPartners (Minnesota and Wisconsin), Intermountain Healthcare (Utah), Kaiser Permanente Northern California (California), Kaiser Permanente Northwest (Oregon and Washington), Regenstrief Institute (Indiana), and University of Colorado (Colorado).
“This study indicates that pregnancy doesn’t diminish mRNA vaccine performance in protecting against severe COVID-19 despite immune differences between pregnant and non-pregnant women,” said study co-author Shaun Grannis, M.D., M.S., vice president for data and analytics at Regenstrief Institute, Regenstrief Professor of Medical Informatics and professor of family medicine at Indiana University School of Medicine. “Vaccine utilization among expectant mothers remains low compared to similarly aged non-pregnant individuals for both the first two vaccines and a booster dose. Hopefully this study will provide pregnant women with the evidence they need to get vaccinated and boosted.”
Current guidance from the Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists recommends that all pregnant women receive two vaccine doses and a booster dose, with a preference for mRNA vaccines.
Weblink: https://www.chemrobotics.com
- AgroPat Lite– Access 5500 pesticides with chemistry, Biology, Regulatory, and IP info. Covers the product information including formulation, combination, developer, innovator, existing intellectual property, regulatory requirement, biology data including spectrum, MOA, DFU, toxicity profile, and safety. (Designed for Business Development function)
-
- AgroPat Ultimate– In detailed Access 5500 pesticides with chemistry, Biology, Regulatory, and IP info. (Designed for Research & Development function)
- Indian Medicine Database –Approved Drugs, Medical Devices, Approved Regenerative Medical Products
- Weblink: https://imd.chemrobotics.com/
- Indian Pesticide Database (IPD)– All Indian Approvals, e.g. 9(3) and 9(4), etc.
- Global Agro Product Directory(More than 55countries approved product info. with relevant documents such as label, factsheet and monograph)
- Weblink: https://www.chemrobotics.com/pesticides-directory/
- Global MRL Database(More than 85 countries MRL info.)
- Jarvis– A Competitor Patents Watch Database for Agrochemical
- Technical Routes(More than 15000 routes of synthesis for Agrochemical & Pharmaceutical)
- Technical Suppliers(Provides technical supplier information)
- Company Directory– KSM Supplier(s) Database — More than 10 K Companies listed from Pharma / Agrochemical / Fine Chemical Domain with their product offering in Pharma / Agrochemical / Fine Chemical segment,
- Weblink: https://companydirectory.chemrobotics.com
- ChemRobotics SPC Database– Provides Patent SPC data Europe
- PharmVetPat –Access chemistry including ROS, KSM, Intermediate, Biology, Regulatory, and IP info for all pharm molecules.
-
- Weblink: https://chemroboticspharma.com/pharmVetPat